OBJECTIVE: To determine the effect of humanized monoclonal antibody against alpha4 integrin (reactive with alpha4beta1 integrin or very-late antigen-4) on MRI lesion activity in MS. METHODS: A randomized, double-blind, placebo-controlled trial in 72 patients with active relapsing-remitting and secondary progressive MS was performed. Each patient received two IV infusions of anti-alpha4 integrin antibody (natalizumab; Antegren) or placebo 4 weeks apart and was followed up for 24 weeks with ser...Expand abstract
- Publication date:
- Source identifiers:
- Local pid:
- Copyright date:
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
If you are the owner of this record, you can report an update to it here: Report update to this record